SAREPTA THERAPEUTICS, INC. Other Nonoperating Expense
SAREPTA THERAPEUTICS, INC. (SRPT) reported Other Nonoperating Expense of $285.00 thousand for the 3-month period ending 2023-03-31, per its 10-Q filed 2023-05-02.
Discontinued › Income Statement › Other Income
us-gaap:OtherNonoperatingExpense · last filed 2023-05-02
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for the quarter ending 2023-03-31 was $285.00K, a 83.08% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for the quarter ending 2022-12-31 was -$5.53M, a 134.38% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for the quarter ending 2022-09-30 was $6.32M, a 69.38% decline year-over-year.
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for the quarter ending 2022-06-30 was $16.96M, a 4.79% increase year-over-year.
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for fiscal 2022 was $35.02M, a 48.83% decline from fiscal 2021.
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for fiscal 2021 was $68.44M, a 31.68% increase from fiscal 2020.
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for fiscal 2020 was $51.97M, a 524.88% increase from fiscal 2019.
- SAREPTA THERAPEUTICS, INC. other nonoperating expense for fiscal 2019 was $8.32M, a 56.18% decline from fiscal 2018.
| Period end | Other Nonoperating Expense 3 month | Other Nonoperating Expense 3 month as first filed | Other Nonoperating Expense 6 month | Other Nonoperating Expense 9 month | Other Nonoperating Expense 12 month |
|---|---|---|---|---|---|
| 2023-03-31 | $285.00K 10-Q · filed 2023-05-02 | -$5.24M derived: sum of 2 quarters · filed 2023-05-02 | $1.08M derived: sum of 3 quarters · filed 2023-05-02 | $18.04M derived: sum of 4 quarters · filed 2023-05-02 | |
| 2022-12-31 | -$5.53M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $795.00K derived: sum of 2 quarters · filed 2023-02-28 | $17.76M derived: sum of 3 quarters · filed 2023-02-28 | $35.02M 10-K · filed 2023-02-28 | |
| 2022-09-30 | $6.32M 10-Q · filed 2022-11-02 | $23.28M derived: sum of 2 quarters · filed 2022-11-02 | $40.55M 10-Q · filed 2022-11-02 | $41.04M derived: sum of 4 quarters · filed 2023-05-02 | |
| 2022-06-30 | $16.96M 10-Q · filed 2022-08-02 | $34.23M 10-Q · filed 2022-08-02 | $34.72M derived: sum of 3 quarters · filed 2023-05-02 | $55.37M derived: sum of 4 quarters · filed 2023-05-02 | |
| 2022-03-31 | $1.68M 10-Q · filed 2023-05-02 | $17.27M 10-Q · filed 2022-05-04 | $17.76M derived: sum of 2 quarters · filed 2023-05-02 | $38.41M derived: sum of 3 quarters · filed 2023-05-02 | $54.59M derived: sum of 4 quarters · filed 2023-05-02 |
| 2021-12-31 | $16.08M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $36.73M derived: sum of 2 quarters · filed 2023-02-28 | $52.91M derived: sum of 3 quarters · filed 2023-02-28 | $68.44M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $20.65M 10-Q · filed 2022-11-02 | $36.83M derived: sum of 2 quarters · filed 2022-11-02 | $52.36M 10-Q · filed 2022-11-02 | $70.13M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-06-30 | $16.18M 10-Q · filed 2022-08-02 | $31.71M 10-Q · filed 2022-08-02 | $49.48M derived: sum of 3 quarters · filed 2023-02-28 | $63.82M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2021-03-31 | $15.53M 10-Q · filed 2022-05-04 | $33.30M derived: sum of 2 quarters · filed 2023-02-28 | $47.63M derived: sum of 3 quarters · filed 2023-02-28 | $60.08M derived: sum of 4 quarters · filed 2023-02-28 | |
| 2020-12-31 | $17.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $32.10M derived: sum of 2 quarters · filed 2023-02-28 | $44.55M derived: sum of 3 quarters · filed 2023-02-28 | $51.97M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $14.34M 10-Q · filed 2021-11-03 | $26.78M derived: sum of 2 quarters · filed 2021-11-03 | $34.20M 10-Q · filed 2021-11-03 | $38.98M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $12.45M 10-Q · filed 2021-08-04 | $19.87M 10-Q · filed 2021-08-04 | $24.64M derived: sum of 3 quarters · filed 2022-03-01 | $27.15M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $7.42M 10-Q · filed 2021-05-05 | $12.19M derived: sum of 2 quarters · filed 2022-03-01 | $14.70M derived: sum of 3 quarters · filed 2022-03-01 | $15.56M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2019-12-31 | $4.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $7.28M derived: sum of 2 quarters · filed 2022-03-01 | $8.14M derived: sum of 3 quarters · filed 2022-03-01 | $8.32M 10-K · filed 2022-03-01 | |
| 2019-09-30 | $2.51M 10-Q · filed 2020-11-05 | $3.37M derived: sum of 2 quarters · filed 2020-11-05 | $3.54M 10-Q · filed 2020-11-05 | $5.86M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-06-30 | $862.00K 10-Q · filed 2020-08-05 | $1.03M 10-Q · filed 2020-08-05 | $3.35M derived: sum of 3 quarters · filed 2021-03-01 | $10.31M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2019-03-31 | $172.00K 10-Q · filed 2020-05-06 | $2.48M derived: sum of 2 quarters · filed 2021-03-01 | $9.45M derived: sum of 3 quarters · filed 2021-03-01 | $14.67M derived: sum of 4 quarters · filed 2021-03-01 | |
| 2018-12-31 | $2.31M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $9.28M derived: sum of 2 quarters · filed 2021-03-01 | $14.50M derived: sum of 3 quarters · filed 2021-03-01 | $18.98M 10-K · filed 2021-03-01 | |
| 2018-09-30 | $6.97M 10-Q · filed 2019-11-07 | $12.19M derived: sum of 2 quarters · filed 2019-11-07 | $16.67M 10-Q · filed 2019-11-07 | ||
| 2018-06-30 | $5.22M 10-Q · filed 2019-08-07 | $9.70M 10-Q · filed 2019-08-07 | |||
| 2017-12-31 | $1.99M 10-K · filed 2020-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |